Crossmark

An alternatively spliced PD-L1 isoform PD-L1∆3, and PD-L2 expression in breast cancers: implications for eligibility scoring and immunotherapy response

Crossref DOI link: https://doi.org/10.1007/s00262-023-03543-y

Published Online: 2023-09-28

Published Print: 2023-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Dioken, Didem Naz https://orcid.org/0000-0001-8285-8147
Ozgul, Ibrahim https://orcid.org/0000-0001-7016-3188
Yilmazbilek, Irem https://orcid.org/0009-0002-6715-6192
Yakicier, Mustafa Cengiz

Karaca, Ezgi https://orcid.org/0000-0002-4926-7991
Erson-Bensan, Ayse Elif https://orcid.org/0000-0001-7398-9313
Funding

Funding for this research was provided by:

European Molecular Biology Organization (4421, 4421)
License Information

Text and Data Mining valid from 2023-09-28

Version of Record valid from 2023-09-28
More Information

Article History

Received: 15 July 2023

Accepted: 5 September 2023

First Online: 28 September 2023

Declarations

:

: The authors have no relevant financial or non-financial interests to disclose.

Document is current

Any future updates will be listed below